The first report of clonidine in vivo/in vitro effects on infertile women with polycystic ovary syndrome (in vivo/in vitro study)

Zangeneh FZ 1 , Muhammadnejad S 2 , Naghizadeh MM 3 , Jafarabadi M 1 , Sarmast Shoushtari M 4 , Masoumi M 5

Affiliations 

  • 1 Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran
  • 2 Cell-Based Therapies Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  • 3 Non-communicable Disease Research Center, Fasa University of Medical Science, Fasa, Iran
  • 4 Bio-material Engineering, Chemical and Environmental Engineering Department, Engineering Faculty, Universiti Putra Malaysia, Serdang, Malaysia
  • 5 Medical Genetics, Faculty of Basic Sciences, Biology Group, Islamic Azad University, Tehran, Iran
J Obstet Gynaecol, 2021 Nov 01.
PMID: 34720019 DOI: 10.1080/01443615.2021.1963221

Abstract

The sympathetic nervous system (SNS) is hyperactive in women with polycystic ovary syndrome (PCOS). This study was designed in two sections: in vivo/in vitro with clonidine as the alpha-2 adrenoceptor (ADR-α2) agonist for modulating this hyperactivity. Eighty women with PCO participated in this randomised clinical trial (in vivo). A clonidine (0.1 mg) tablet was given twice a day for two months. Polycystic ovary morphology (PCOM) and pregnancy rate were the main outcome measurements. In the candidates for in vitro fertilisation (IVF), clonidine was added to the culture medium during IVF for two study groups (PCO-clonidine/PCO-without) and two control groups (egg donors-clonidine/egg donors-without). Our results showed that the pregnancy rate significantly was higher in the study group (p = .002). The mRNA expression of ADR-α1 and ADR-β2 in PCO was higher than control group (p value

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications